glp 1 risk of cancer Glucagon-like peptide-1 receptor agonists and gastrointestinal cancers: A systematic review and meta-analysis of randomized controlled trials Glucagon-like peptide 1 receptor agonists

Menstrual cycle considerations For people with endometriosis, anything that affects the menstrual cycle warrants attention

Tirzepatide came off the FDA shortage list in December 2024 (enforcement discretion ended March 2025)

\n\nIn your clinical practice, how early are you introducing SGLT2 inhibitors into the journey of the non-diabetic chronic kidney disease patient, and how do you manage the concern over the initial drop in glomerular filtration at the start of treatment

Additionally, the combined insulin and GLP-1 mechanism of action may not have the same broad appeal in a market dominated by stand-alone GLP-1 drugs

Pratley et al

These take the form of orally-administered pills or injectables that can be taken at a lower frequency, both of which have the potential to bring down costs and increase the appeal for patients who dislike self-injection